Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 901312, 5 pages
http://dx.doi.org/10.1155/2015/901312
Research Article

Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

1Department of Biomedical and Specialist Surgical Sciences, University of Ferrara, 44124 Ferrara, Italy
2Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy
3Department of General Neurology, National Neurological Institute C. Mondino, 27100 Pavia, Italy
4Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy
5Department of Neurosciences and Rehabilitation, Azienda Ospedaliero-Universitaria, 44124 Ferrara, Italy

Received 15 February 2015; Accepted 17 May 2015

Academic Editor: Mariann Harangi

Copyright © 2015 Massimiliano Castellazzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Massimiliano Castellazzi, Serena Delbue, Francesca Elia, et al., “Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment,” Disease Markers, vol. 2015, Article ID 901312, 5 pages, 2015. doi:10.1155/2015/901312